India · Delayed Price · Currency is INR Neuland Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 revenue grew 11.4% year-over-year, driven by CMS projects, though gross margin declined due to product mix and absence of high-margin products. Capacity expansions and new CMS molecules are expected to drive growth, with a strong pipeline and investments in peptides positioning the business for long-term success.
-
Q2 FY2026 saw a 63.7% revenue surge to INR 516 crore, led by CMS/CDMO growth and improved margins. Strong customer engagement, new capacity, and ongoing investments support a positive outlook, though risks from market volatility and uneven business remain.
-
Q1 FY26 saw a 32.4% revenue decline and margin compression due to uneven order flow, but management remains optimistic about strong FY26 growth as new capacities and commercial molecules ramp up. Peptide investments and CMS pipeline expansion are on track.
Fiscal Year 2025
-
Q4 and FY25 saw revenue and profit declines due to product mix and lifecycle effects, but strong free cash flow and reduced net debt position the company for growth. New capacity and product launches are expected to drive a rebound in FY26, with CMS and GDS segments both set to grow.
-
Q3 saw modest revenue growth and a strong profit after tax due to an exceptional gain, though margins declined year-over-year. FY25 is expected to be flat, with growth resuming in FY26, supported by capacity expansion and a robust order pipeline. Major investments in peptides and improved ESG ratings highlight strategic progress.
-
Q2 FY25 saw a sharp year-over-year revenue and profit decline, with management expecting FY25 to be flat but projecting strong growth from FY26 as new facilities and commercial launches come online. CMS and GDS segments remain balanced, with robust order pipelines and continued investment in capacity and technology.
-
Q1 FY25 saw 21.7% revenue growth, strong CMS performance, and improved margins. Management expects FY25 to be a year of consolidation with normalized growth and margins, with momentum picking up from FY26 as new capacities come online.